Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crispr Therapeutics AG (CRSP – Research Report), Alcon (ALC – Research Report) and Outset Medical (OM – Research Report).
Crispr Therapeutics AG (CRSP)
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on Crispr Therapeutics AG, with a price target of $97.00. The company’s shares closed last Wednesday at $82.41, close to its 52-week high of $90.18.
According to TipRanks.com, Biliouris is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Crispr Therapeutics AG with a $86.45 average price target, representing a 4.8% upside. In a report issued on February 7, Truist Financial also maintained a Buy rating on the stock with a $120.00 price target.
See the top stocks recommended by analysts >>
Alcon (ALC)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Alcon, with a price target of $89.00. The company’s shares closed last Wednesday at $79.78.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $85.43 average price target, which is an 8.9% upside from current levels. In a report issued on February 6, KeyBanc also initiated coverage with a Buy rating on the stock with a $87.00 price target.
Outset Medical (OM)
In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Outset Medical, with a price target of $5.00. The company’s shares closed last Wednesday at $3.21, close to its 52-week low of $2.74.
According to TipRanks.com, Chadha is a 3-star analyst with an average return of
Currently, the analyst consensus on Outset Medical is a Moderate Buy with an average price target of $6.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRSP:
- CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Crispr Therapeutics reports Q4 EPS $1.10, consensus (7c)
- Crispr Therapeutics options imply 7.2% move in share price post-earnings
- CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit
- Crispr Therapeutics initiated with a Peer Perform at Wolfe Research
